Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...

Campbell Soup Earnings Are Good Food for Investors

Now serving much more than just soup, shares of multi-brand food conglomerate Campbell Soup Co. are trading 10% higher today as the firm announced better than expected annual earnings. Shares of Campbell Soup Company (CPB:NYSE) are trading more than 10% higher today...

Lifeway Foods' Shares Rise 40% on Positive Q1 Sales Data with March Revenue Up 13% Y-O-Y

Shares of Lifeway Foods traded higher as the company reported it has increased production to support accelerated demand during the COVID-19 health crisis. Lifeway Foods Inc. (LWAY:NASDAQ) yesterday provided a business update together with reporting its Q4...

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics...

Introducing: The Device to Replace Antiquated Paper-Based Systems

(Image via Visionstate Corp. Click to enlarge.) The Internet of Things (IoT) describes the network of physical objects “things” that are embedded with sensors, software, and other technologies for the purpose of connecting and exchanging data ...

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. In an Aug. 8 research note, analyst Joseph Pantginis reviewed Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Q2/19 financials and reported t...

'Topline Beat, All Eyes on Potential M&A' by Health Technologies Firm

An update on the Canadian company, including its Q2/19 results and its next expected catalyst, is provided in a Haywood report. In an Aug. 23 research note, analyst Daniel Rosenberg reported that his firm Haywood increased its price target on WELL Health Technologies...

Manufacturing Goes Deeper Into Recession, Yet Gold Remains Muted. Why?

The ISM Manufacturing index fell 0.2 point to a reading of 48.1 in November. However, gold struggles to find momentum. What is going on exactly? U.S. Manufacturing Sector Slumps Further The Institute for Supply Management announced that its index of national factory a...

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $...

Oil & Gas Firm Responds to Oil Price Drop

Occidental Petroleum's two recent moves are reviewed and commented on in a Raymond James report. In a March 10 research note, Raymond James analyst Pavel Molchanov reported that Occidental Petroleum Corp. (OXY:NYSE) cut both its capex and dividend in respo...
1 2 3 4 5 6 7 8 9 10 ...